At the ESC 2025 Congress in Madrid, researchers from the Federal University of Minas Gerais, Brazil, presented a large systematic review and meta-analysis evaluating the role of telemedicine in oral anticoagulation management. The findings confirm that telehealth can improve therapeutic quality without compromising safety.

The review covered 39 randomized clinical trials published up to July 2024, involving 119,734 patients with an average age of 75 years. Telemedicine interventions included self-testing with remote mobile management, computer-assisted dosing, laboratory testing with remote dose adjustment, and multipurpose health applications.

Results showed that telemedicine significantly increased the proportion of time patients on warfarin remained within the therapeutic range (mean difference 4.61, 95% CI 1.60–7.62). A favorable trend was also observed in reducing thromboembolic events (RR 0.85), while no differences were detected in mortality (RR 0.98) or major bleeding risk (RR 0.92). Importantly, safety outcomes remained consistent across all types of interventions.

The study emphasizes telemedicine’s growing role in cardiovascular care, particularly for elderly patients requiring lifelong anticoagulation. Future research may focus on optimizing telehealth platforms, integrating artificial intelligence for dosing decisions, and expanding access in low-resource settings. As healthcare systems increasingly shift toward digital solutions, the findings presented at ESC 2025 may help shape global strategies for safer, more efficient anticoagulation management.